Enteric Disease Testing in United States Trends and Forecast
The future of the enteric disease testing market in United States looks promising, with opportunities in the water and food markets. The global enteric disease testing market is expected to reach an estimated $5.1 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The enteric disease testing market in United States is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising number of innovations and technological advancements in enteric disease testing devices, increasing focus on sample utilization, and growing advancements for quicker, proficient, and cheaper computing hardware tied with better network connectivity.
• Lucintel forecasts that, within the technology category, traditional testing will remain the largest segment over the forecast period due to growing demand for processed and convenience food, as well as increasing incidences of enteric diseases.
Emerging Trends in the Enteric Disease Testing Market in United States
The enteric disease testing market in the United States is experiencing dynamic shifts, driven by advances in diagnostic technology, growing awareness of foodborne illnesses, and a commitment to improving public health. As enteric diseases continue to impact large portions of the population, particularly through contaminated food and water, innovative testing methods are crucial for accurate, timely diagnosis. The integration of molecular diagnostics, AI-driven solutions, and rapid testing technologies is transforming how these diseases are detected and managed in the U.S.
• Molecular Diagnostics and PCR Testing: Molecular diagnostics, especially PCR (polymerase chain reaction) testing, are leading the charge in the U.S. for enteric disease testing. These technologies enable the detection of pathogens at the genetic level, allowing for high specificity and sensitivity. PCR offers faster results and the ability to detect pathogens even at low levels. The widespread adoption of molecular diagnostics is improving the speed and accuracy of diagnosing enteric diseases, thus enhancing patient outcomes and aiding public health efforts.
• AI and Data-Driven Diagnostics: Artificial intelligence (AI) is increasingly being incorporated into the analysis of enteric disease test results. By using machine learning algorithms, AI can process large volumes of patient data and identify patterns that may not be immediately obvious to clinicians. This leads to more accurate diagnoses and faster decision-making. AI-powered diagnostic platforms are helping healthcare providers analyze test results more effectively, streamlining workflows and enhancing the efficiency of the testing process.
• Expansion of Point-of-Care Testing: Point-of-care (POC) testing is gaining traction in the U.S., with more diagnostic platforms being developed for on-site testing of enteric diseases. These tests, which can be performed in settings such as doctors’ offices, clinics, or even at home, allow for immediate results. POC testing reduces waiting times for diagnoses, enabling faster treatment and minimizing the spread of infections, particularly in cases of foodborne outbreaks where time is of the essence.
• Increased Focus on Foodborne Pathogen Detection: In response to rising concerns over foodborne illnesses, there has been an increase in investment and innovation in food safety testing. The U.S. government, in collaboration with the private sector, is improving foodborne pathogen detection technologies. Rapid and accurate detection methods are now being applied across food production and distribution channels, helping to ensure public safety and prevent widespread outbreaks, especially as the food supply chain becomes increasingly globalized.
• Government Regulations and Enhanced Surveillance: The U.S. government has been actively strengthening regulations regarding food safety and enteric disease testing. Agencies such as the FDA and CDC are enhancing surveillance systems and implementing new guidelines to monitor and prevent enteric disease outbreaks. Improved reporting mechanisms and data collection are enabling authorities to respond more swiftly and effectively to public health risks, ultimately leading to better control of foodborne disease outbreaks.
Emerging trends such as the adoption of molecular diagnostics, the integration of AI, the expansion of point-of-care testing, enhanced food safety measures, and stronger government regulations are reshaping the enteric disease testing landscape in the United States. These innovations are improving diagnostic accuracy, reducing testing times, and enabling better disease management, ultimately contributing to improved public health responses and patient care.
Recent Developments in the Enteric Disease Testing Market in United States
In recent years, significant developments in technology, healthcare policy, and public health strategies have reshaped the enteric disease testing market in the United States. These advancements are improving disease detection, treatment times, and patient outcomes. The market is rapidly evolving, driven by the increased need for faster, more accurate diagnostics, and enhanced response mechanisms to combat foodborne diseases.
• Introduction of Whole Genome Sequencing (WGS): Whole genome sequencing (WGS) has become a critical tool in enteric disease testing, enabling more comprehensive analysis of pathogens. WGS allows for the identification of genetic variations in bacteria and viruses, offering precise information about the source and spread of outbreaks. This technology has been particularly valuable in tracing foodborne illness outbreaks, improving the ability to track pathogens, and ensuring more targeted public health responses.
• FDA Approval of Rapid Diagnostic Tests: The FDA has recently approved several rapid diagnostic tests (RDTs) for detecting enteric pathogens. These tests are significantly faster than traditional methods, providing results in hours instead of days. As a result, healthcare providers can initiate treatment more quickly, reducing the burden on healthcare facilities and improving patient outcomes. These RDTs are also being deployed in more locations, including point-of-care settings, increasing accessibility and convenience for patients.
• Increased Public-Private Collaborations for Food Safety: There has been a notable increase in collaborations between public health agencies and private companies to improve foodborne pathogen detection. These partnerships have led to the development of new technologies and innovations that expedite testing, improve accuracy, and enhance overall food safety. Collaborative efforts are also helping streamline regulatory processes, allowing for faster approval and deployment of new diagnostic solutions.
• Surge in Investment for Diagnostic Innovations: The United States has seen an uptick in investments for the development of innovative diagnostic solutions for enteric diseases. This surge is driven by the rising demand for faster, more accurate testing methods. Investment is also being channeled into research aimed at developing more affordable and accessible diagnostic tools. As a result, diagnostic companies are rapidly innovating, leading to the expansion of test offerings and improvements in overall disease detection.
• Expansion of State and Federal Disease Surveillance Programs: State and federal agencies in the U.S. have expanded disease surveillance programs to better monitor enteric disease outbreaks. Enhanced data collection, monitoring systems, and the use of advanced analytics have improved real-time outbreak detection. These programs are essential for identifying trends, allocating resources effectively, and preventing widespread outbreaks.
Recent developments, such as the introduction of whole genome sequencing, FDA approval of rapid diagnostic tests, increased public-private collaborations, investment in diagnostic innovations, and the expansion of disease surveillance programs, are revolutionizing the enteric disease testing market in the United States. These advancements are making diagnostics faster, more accurate, and more accessible, contributing to improved public health management and disease control.
Strategic Growth Opportunities for Enteric Disease Testing Market in United States
The enteric disease testing market in the United States presents several strategic growth opportunities, driven by advancements in diagnostics, rising awareness about foodborne diseases, and growing demands for more efficient disease monitoring. Key applications, including point-of-care testing, molecular diagnostics, and food safety technologies, offer ample opportunities for market expansion.
• Point-of-Care (POC) Testing Expansion: The demand for point-of-care testing is growing rapidly, as it allows for immediate diagnosis without the need for laboratory visits. POC testing platforms are becoming more widely used in healthcare facilities, clinics, and home settings. By offering faster results and reducing the need for patients to wait for lab tests, POC testing is improving patient care and reducing healthcare costs.
• Molecular Diagnostics Growth: Molecular diagnostics are experiencing rapid growth, providing a key growth opportunity in the U.S. market. Technologies like PCR and next-generation sequencing (NGS) are transforming the way enteric diseases are diagnosed. These methods offer high sensitivity and accuracy, making them particularly valuable for detecting pathogens that are difficult to identify with traditional methods. As the cost of molecular diagnostics decreases, the market is expected to expand further.
• Integration of Artificial Intelligence (AI) in Diagnostics: AI is playing an increasingly important role in enhancing the capabilities of enteric disease testing. By applying machine learning algorithms to diagnostic data, AI can help identify trends, improve test accuracy, and speed up the decision-making process. As AI technology continues to improve, it will create significant opportunities for enhancing the efficiency and precision of diagnostics in enteric disease testing.
• Advancements in Foodborne Pathogen Detection: With the increasing importance of food safety, there is a growing opportunity for the development of advanced pathogen detection solutions. Innovations in testing methods and technologies are enabling faster detection of foodborne pathogens, particularly in the supply chain. The growth of global trade and the complexity of the food industry create a significant market for more reliable and rapid food safety testing.
• Government and Healthcare Initiatives: Federal and state-level initiatives aimed at improving public health through better disease surveillance and faster diagnostics present growth opportunities. Increased funding and support for research into enteric diseases and diagnostic technologies are driving innovation. Government-backed initiatives are helping to create a favorable environment for the expansion of enteric disease testing technologies, furthering their adoption in healthcare and public health systems.
Strategic growth opportunities in point-of-care testing, molecular diagnostics, AI integration, food safety innovations, and government initiatives are shaping the future of the enteric disease testing market in the United States. These areas offer significant potential for enhancing diagnostic capabilities, improving public health outcomes, and driving market expansion.
Enteric Disease Testing Market in United States Driver and Challenges
The enteric disease testing market in the United States is influenced by several key drivers, including technological advancements, government support, and the rising prevalence of foodborne diseases. At the same time, challenges such as the high cost of advanced diagnostics, regulatory hurdles, and healthcare access disparities must be addressed to ensure sustainable market growth.
The factors responsible for driving the enteric disease testing market in United States include:
• Technological Advancements: Advances in molecular diagnostics, AI, and point-of-care testing technologies are driving the growth of the enteric disease testing market. These technologies enable faster, more accurate detection of pathogens, improving diagnosis and patient care.
• Increasing Demand for Rapid Diagnostics: The growing need for rapid and accurate diagnostics, particularly in outbreak situations, is propelling the market. Point-of-care testing and molecular diagnostics are becoming more widely adopted to provide quick results, reducing delays in treatment and minimizing the risk of disease transmission.
• Government Support and Funding: The U.S. government has invested heavily in public health initiatives and research related to foodborne diseases and diagnostics. This support has fostered innovation and facilitated the development of new testing technologies, driving the growth of the market.
• Rising Foodborne Disease Incidents: Increasing incidents of foodborne diseases are fueling the demand for better diagnostic solutions. Outbreaks linked to contaminated food have highlighted the need for more advanced testing methods, propelling market growth.
• Healthcare System Demand for Improved Diagnostics: As healthcare providers seek more efficient ways to diagnose enteric diseases, there is a growing demand for advanced testing solutions that can quickly and accurately detect pathogens. This is driving the adoption of molecular diagnostics and other rapid testing methods.
Challenges in the enteric disease testing market in United States are:
• High Testing Costs: The cost of advanced testing technologies, such as molecular diagnostics and next-generation sequencing, remains a significant challenge. These tests are often expensive to develop and implement, which limits their widespread adoption, particularly in low-resource settings.
• Regulatory Barriers: The lengthy and complex regulatory approval process for new diagnostic tests can slow the development and introduction of new technologies. Stringent regulatory requirements can also lead to delays in the availability of innovative solutions.
• Unequal Access to Healthcare: Despite advancements in diagnostics, disparities in healthcare access persist across the United States. Rural and underserved areas may lack the necessary infrastructure and resources to implement advanced diagnostic solutions, limiting the overall reach of these technologies.
Technological advancements, increasing demand for rapid diagnostics, and government support are driving the growth of the enteric disease testing market in the U.S. However, challenges such as high testing costs, regulatory barriers, and unequal access to healthcare must be overcome to fully realize the potential of these innovations and expand market reach.
List of Enteric Disease Testing Market in United States Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, enteric disease testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the enteric disease testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
Enteric Disease Testing Market in United States by Segment
The study includes a forecast for the enteric disease testing market in United States by technology and end use.
Enteric Disease Testing Market in United States by Technology [Analysis by Value from 2019 to 2031]:
• Traditional
• Rapid
• Convenience-Based
• Polymerase Chain Reaction
• Immunoassay
• Chromatography & Spectrometry
Enteric Disease Testing Market in United States by End Use [Analysis by Value from 2019 to 2031]:
• Food
• Water
Features of the Enteric Disease Testing Market in United States
Market Size Estimates: Enteric disease testing in United States market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Enteric disease testing in United States market size by technology and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different technologies and end uses for the enteric disease testing in United States.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the enteric disease testing in United States.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q.1 What are the major drivers influencing the growth of the enteric disease testing market in United States?
Answer: The major drivers for this market are the rising number of innovations and technological advancements in enteric disease testing devices, increasing focus on sample utilization, and growing advancements for quicker, proficient, and cheaper computing hardware tied with better network connectivity.
Q2. What are the major segments for enteric disease testing market in United States?
Answer: The future of the enteric disease testing market in United States looks promising, with opportunities in the water and food markets.
Q3. Which enteric disease testing market segment in United States will be the largest in future?
Answer: Lucintel forecasts that traditional testing will remain the largest segment over the forecast period due to growing demand for processed and convenience food, as well as increasing incidences of enteric diseases.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the enteric disease testing market in United States by technology (traditional, rapid, convenience-based, polymerase chain reaction, immunoassay, and chromatography & spectrometry) and end use (food and water)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Enteric Disease Testing Market in United States, Enteric Disease Testing Market in United States Size, Enteric Disease Testing Market in United States Growth, Enteric Disease Testing Market in United States Analysis, Enteric Disease Testing Market in United States Report, Enteric Disease Testing Market in United States Share, Enteric Disease Testing Market in United States Trends, Enteric Disease Testing Market in United States Forecast, Enteric Disease Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.